BRIEF-Exelixis announces phase 1 trial results for cabozantinib in combination with nivolumab with or without ipilimumab
February 17, 2017 at 17:07 PM EST
* Exelixis announces phase 1 trial results for cabozantinib in combination with nivolumab with or without ipilimumab in refractory metastatic urothelial carcinoma and other genitourinary tumors
